Niflumic acid

SKU: orb1225048

Description

Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 4394-00-7
• MW: 282.22
• Purity: >98% (HPLC)
• Formula: C₁₃H₉F₃N₂O₂
• SMILES: O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O
• Target: COX
• Solubility: DMSO: 56 mg/mL (198.42 mM)

Bioactivity

• In Vivo:
  Animal model: Pig with asthma. Dosage: 30 mg/kg. Administration: Inhalation. Result: Showed significantly inhibiting the decrease in mucus area.
• In Vitro:
  Cell Viability Assay Cell line: A549, H460, and H1299 cells. Concentration: 0 μM, 100 μM, 200 μM, 300 μM. Incubation time: 48 h. Result: Showed a marked synergistic decrease in cell viability with Ciglitazone. Apoptosis Analysis Cell line: A549, H460, and H1299 cells. Concentration: 100 μM, 200 μM. Incubation time: 48 h. Result: Showed a marked synergistic increase apoptosis with Ciglitazone. Cell Viability Assay Cell line: A549, H460, and H1299 cells. Concentration: 100 μM. Incubation time: 30 h. Result: Showed a marked synergistic increase of proteins level of caspase-8, Bid, and Bax with Ciglitazone.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Actol | Donalgin | Nifluril | UP83

Quick Database Links

Gene Symbol

COX